Although more research is required, the results of this study show that this combination may be a potential game-changer in the future and could help to eradicate minimal residual disease and increase cure in neuroblastoma patients with confirmed SSTR2 expression and wt-p53 mutational status. The gene discussed is SSTR2; the disease is neuroblastoma.